This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Outcomes assessed in the review
The outcomes assessed were the efficacy (in terms of the probability of preventing MAC) and toxicity data associated with each strategy.
Study designs and other criteria for inclusion in the review
No specific study designs were stipulated by the authors as inclusion criteria although all were randomised controlled trials.
Sources searched to identify primary studies
Not stated.
Criteria used to ensure the validity of primary studies
Methods used to judge relevance and validity, and for extracting data
Number of primary studies included
3 primary studies were included in the review.
Methods of combining primary studies
Narrative method.
Investigation of differences between primary studies
Results of the review
The probabilities of preventing MAC for rifabutin, azithromycin and clarithromycin were 0.5146, 0.6335 and 0.7199, respectively. The probabilities of major symptoms or toxicity for rifabutin, azithromycin and clarithromycin were 0.2833, 0.2243 and 0.2564, respectively. The overall likelihood of developing MAC was 18% with placebo and 9% with rifabutin over a mean of 222 days. Minor toxicity or symptoms developed in 42% of patients receiving placebo and 46% of patients receiving rifabutin. Major toxicity occurred in 17% and 22% of patients.
Measure of benefits used in the economic analysis
The outcome measures of benefit were life years gained and quality-adjusted life expectancy. These were estimated from a global quality of life question from AIDS Clinical Trial Group Protocols. The QOL estimates were 0.8700 (no MAC), 0.5610 (acute MAC), 0.7720 (history of MAC and 0.0054 (major toxicity or symptoms) (decrease in QOL).
Direct costs
Total direct medical costs included the cost of prophylaxis, the cost of treating toxicity related to prophylaxis, the cost of evaluation for suspected MAC and the cost of treating diagnosed MAC. The source of costs was a nation-wide survey reported in Physicians' Fee Reference 1994. The charges were converted to costs by a cost-to-charge ratio. Resources were reported separately from the prices. The quantity/cost boundary adopted was that of the payer. Discounting was not undertaken. The price year was 1994.
Currency

US dollars ($).
Sensitivity analysis
A series of sensitivity analyses was carried out on all model parameters, including initial CD4 count for beginning prophylaxis, to determine the impact on the cost-effectiveness results of changing parameter values. Although there is no broad consensus on what cost-effectiveness ratios may be acceptable from a clinical policy perspective, parameter
Implications of the study
As the authors noted, better data on costs of care could be obtained by including cost studies in parallel with clinical trials as they are conducted. Furthermore, more research is required in which patients are directly comparable with each other in terms of concomitant medications and other characteristics. Better data on drug interactions and clinical outcomes might be included in the cost-effectiveness model. Other important factors such as drug toxicity, patientspecific quality-of-life considerations, the likelihood of drug interactions and geographic or environmental MAC exposure risk should be included in future research.
